White House digs in on ‘most-favored nation’ drug pricing despite Congress’ cool reception

March 17, 2026 - 12:26

Despite facing a notably cool reception on Capitol Hill, the Biden administration is digging in its heels and ramping up pressure on Congress to pass a transformative drug pricing measure. The policy, known as the "most-favored nation" model, aims to fundamentally alter how the U.S. pays for certain high-cost prescription medications.

The approach would tie the price of specific drugs in Medicare to the lower prices paid in other developed nations, a move the administration argues is essential to curb America's uniquely high pharmaceutical costs. Proponents believe it would save taxpayers billions and provide critical relief to seniors.

However, the proposal has encountered significant bipartisan skepticism and legislative hurdles. Key lawmakers have expressed concerns about its implementation, potential impact on innovation, and the complexities of international price-setting. The pharmaceutical industry has launched fierce opposition, warning of reduced access to new therapies.

Undeterred, White House officials are now mobilizing a more aggressive advocacy campaign. This includes direct outreach to legislators and highlighting public support for lowering drug prices, a consistently popular issue among voters. The administration's steadfast commitment signals a contentious political battle ahead as it seeks to deliver on a major campaign promise and alter the nation's healthcare landscape.